Alpha Tau Medical Ltd. (NASDAQ:DRTS) Given Average Rating of “Hold” by Brokerages

Shares of Alpha Tau Medical Ltd. (NASDAQ:DRTS) have been assigned an average rating of “Hold” from the six brokerages that are presently covering the stock, Marketbeat.com reports. One analyst has rated the stock with a sell recommendation, two have given a hold recommendation and three have given a buy recommendation to the company. The average 1 year target price among brokers that have issued a report on the stock in the last year is $11.50.

Several equities research analysts have recently commented on DRTS shares. Piper Sandler lifted their price objective on shares of Alpha Tau Medical from $5.00 to $8.00 and gave the stock a “neutral” rating in a research note on Tuesday. Citigroup lifted their price objective on shares of Alpha Tau Medical from $7.00 to $9.00 and gave the stock a “buy” rating in a research note on Wednesday, March 11th. HC Wainwright reiterated a “buy” rating and set a $15.00 price objective on shares of Alpha Tau Medical in a research note on Wednesday. LADENBURG THALM/SH SH lifted their price objective on shares of Alpha Tau Medical from $12.00 to $14.00 and gave the stock a “buy” rating in a research note on Tuesday, May 12th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Alpha Tau Medical in a report on Monday, April 20th.

Key Headlines Impacting Alpha Tau Medical

Here are the key news stories impacting Alpha Tau Medical this week:

• Positive Sentiment: HC Wainwright kept a Buy rating on Alpha Tau Medical and maintained a $15.00 price objective, implying meaningful upside from current levels.
• Neutral Sentiment: The firm’s latest estimates still point to ongoing losses, with multiple quarters projected at -$0.14 EPS and FY2027 EPS at -$0.55, but these figures were broadly in line with the existing subscale profitability outlook.
• Negative Sentiment: HC Wainwright lowered earnings estimates for Q2 2026, Q3 2026, Q4 2026, and FY2026, signaling a weaker near-term profit outlook for Alpha Tau Medical.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the business. Daytona Street Capital LLC purchased a new position in shares of Alpha Tau Medical during the fourth quarter worth $749,000. Apella Capital LLC purchased a new position in shares of Alpha Tau Medical during the fourth quarter worth $1,892,000. Levin Capital Strategies L.P. raised its holdings in shares of Alpha Tau Medical by 6.3% during the third quarter. Levin Capital Strategies L.P. now owns 204,714 shares of the company’s stock worth $923,000 after purchasing an additional 12,200 shares during the last quarter. Mariner LLC raised its holdings in shares of Alpha Tau Medical by 1.6% during the fourth quarter. Mariner LLC now owns 125,165 shares of the company’s stock worth $620,000 after purchasing an additional 1,915 shares during the last quarter. Finally, Millennium Management LLC raised its holdings in shares of Alpha Tau Medical by 185.7% during the fourth quarter. Millennium Management LLC now owns 107,815 shares of the company’s stock worth $534,000 after purchasing an additional 70,081 shares during the last quarter. Hedge funds and other institutional investors own 2.65% of the company’s stock.

Alpha Tau Medical Trading Down 8.4%

NASDAQ:DRTS opened at $10.04 on Monday. Alpha Tau Medical has a 12 month low of $2.81 and a 12 month high of $11.62. The firm has a fifty day simple moving average of $8.02 and a 200-day simple moving average of $6.55. The company has a current ratio of 7.79, a quick ratio of 7.45 and a debt-to-equity ratio of 0.09. The company has a market capitalization of $883.62 million, a P/E ratio of -14.99 and a beta of 1.11.

Alpha Tau Medical (NASDAQ:DRTS) last posted its quarterly earnings data on Monday, May 18th. The company reported ($0.26) EPS for the quarter, missing the consensus estimate of ($0.13) by ($0.13). On average, equities research analysts anticipate that Alpha Tau Medical will post -0.6 earnings per share for the current year.

Alpha Tau Medical Company Profile

Alpha Tau Medical Ltd. is a medical technology company headquartered in Ness Ziona, Israel, focused on developing targeted alpha-radiation therapies for the treatment of solid tumors. The company’s core innovation, known as Diffusing Alpha-emitters Radiation Therapy (DaRT), employs short-lived radioactive isotopes to deliver high-energy alpha particles directly within or adjacent to tumor tissues. By harnessing the potent cytotoxic effects of alpha radiation, Alpha Tau Medical aims to offer a novel approach to brachytherapy that can potentially overcome radioresistance and spare surrounding healthy tissue.

The company’s lead product, Alpha DaRT, is currently being evaluated in clinical studies for a range of indications including recurrent or metastatic head and neck cancers, skin cancers, and other solid tumors.